• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?

作者信息

Monteverdi Sara, Vita Emanuele, Sartori Giulia, Ferrara Miriam Grazia, D'Argento Ettore, Tortora Giampaolo, Milella Michele, Bria Emilio, Pilotto Sara

机构信息

U.O.C. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Medical Oncology, Università Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Transl Cancer Res. 2020 Feb;9(2):409-414. doi: 10.21037/tcr.2019.12.82.

DOI:10.21037/tcr.2019.12.82
PMID:35117384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8798740/
Abstract
摘要

相似文献

1
Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?晚期非小细胞肺癌免疫治疗的长期幸存者：“治愈”是否触手可及？
Transl Cancer Res. 2020 Feb;9(2):409-414. doi: 10.21037/tcr.2019.12.82.
2
A 'cure' for Down syndrome: what do parents want?唐氏综合征的“治愈”：家长们想要什么？
Clin Genet. 2014 Oct;86(4):310-7. doi: 10.1111/cge.12364. Epub 2014 Mar 21.
3
Role of age and tumour stage in the temporal pattern of 'cure' from stomach cancer: a population-based study in Osaka, Japan.年龄和肿瘤分期在日本大阪胃癌“治愈”时间模式中的作用：一项基于人群的研究。
Cancer Epidemiol. 2012 Apr;36(2):128-32. doi: 10.1016/j.canep.2011.12.008. Epub 2012 Jan 31.
4
Immunotherapy through the Lens of Non-Small Cell Lung Cancer.从非小细胞肺癌视角看免疫疗法
Cancers (Basel). 2023 May 30;15(11):2996. doi: 10.3390/cancers15112996.
5
No 'cure' within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989-2011.通过乳房X光筛查确诊的乳腺癌患者在确诊后12年内无“治愈”情况：1989年至2011年在英格兰西米德兰兹地区确诊的女性。
Ann Oncol. 2016 Nov;27(11):2025-2031. doi: 10.1093/annonc/mdw408. Epub 2016 Aug 29.
6
Long term survivors of childhood cancer: cure and care. The Erice statement.儿童癌症长期幸存者：治愈与照护。埃里切声明。
Eur J Cancer. 2007 Aug;43(12):1778-80. doi: 10.1016/j.ejca.2007.04.015. Epub 2007 May 31.
7
Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: the effects of parasite dose, cyclophosphamide and sublethal irradiation.小鼠对杜氏利什曼原虫感染的基因控制获得性反应的免疫调节：寄生虫剂量、环磷酰胺和亚致死剂量照射的影响
Parasite Immunol. 1983 Sep;5(5):449-63. doi: 10.1111/j.1365-3024.1983.tb00760.x.
8
Re-examining the HIV 'functional cure' oxymoron: Time for precise terminology?重新审视“HIV功能性治愈”这一矛盾修辞：是时候采用精确术语了？
J Virus Erad. 2020 Oct 14;6(4):100017. doi: 10.1016/j.jve.2020.100017. eCollection 2020 Nov.
9
Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer?回首过去，展望未来：我们是否正在改善非小细胞肺癌的“治愈”情况？
Eur J Cancer. 2017 Apr;75:192-194. doi: 10.1016/j.ejca.2017.01.006. Epub 2017 Feb 23.
10
How physicians describe outcomes to HCV therapy: prevalence and meaning of "cure" during provider-patient in-office discussions of HCV.医生如何向丙型肝炎患者描述治疗结果：在医患办公室关于丙型肝炎的讨论中“治愈”的发生率及含义
J Clin Gastroenterol. 2008 Apr;42(4):419-24. doi: 10.1097/MCG.0b013e318032337b.

引用本文的文献

1
Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy.抗生素对免疫检查点抑制剂疗法抗肿瘤疗效的影响。
Clin Transl Oncol. 2025 Feb;27(2):790-799. doi: 10.1007/s12094-024-03615-0. Epub 2024 Jul 24.
2
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.非小细胞肺癌：从肿瘤发生、免疫检查点滥用到当前和未来的靶向治疗。
Front Immunol. 2024 Feb 7;15:1342086. doi: 10.3389/fimmu.2024.1342086. eCollection 2024.
3
Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer.衰老标记蛋白30通过降低非小细胞肺癌中HDAC4的表达来抑制肿瘤生长。
Transl Lung Cancer Res. 2021 Dec;10(12):4558-4573. doi: 10.21037/tlcr-21-982.

本文引用的文献

1
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.阿替利珠单抗联合卡铂和白蛋白紫杉醇治疗晚期鳞状 NSCLC（IMpower131）：一项随机 III 期试验的结果。
J Thorac Oncol. 2020 Aug;15(8):1351-1360. doi: 10.1016/j.jtho.2020.03.028. Epub 2020 Apr 14.
2
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
3
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
4
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
5
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis.用于选择非小细胞肺癌患者进行一线免疫化疗联合治疗的程序性死亡受体配体1（PD-L1）：一项系统评价和荟萃分析
Immunotherapy. 2019 Jul;11(10):921-930. doi: 10.2217/imt-2018-0198. Epub 2019 Jun 3.
6
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.帕博利珠单抗治疗晚期非小细胞肺癌患者的 5 年总生存结果：来自 I 期 KEYNOTE-001 研究的结果。
J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.
7
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
8
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
9
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
10
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.